Jaguar Health, Inc. (JAGX): Cash & Equivalents
$968.0K
As of 2025-12-31
$3.79M
As of 2026-06-30
-43.9%
3-year compound annual growth
-34.6%
5-year compound annual growth
-18.7%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $968.0K | -87.9% | 2026-04-07, Balance as of period end |
| 2024-12-31 | $8.00M | +23.7% | 2026-04-07, Balance as of period end |
| 2023-12-31 | $6.47M | +18.3% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $5.47M | -67.9% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $17.05M | +110.8% | 2023-03-24, Balance as of period end |
| 2020-12-31 | $8.09M | +131.5% | 2021-03-31, Balance as of period end |
| 2019-12-31 | $3.50M | +36.1% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $2.57M | +393.2% | 2020-04-03, Balance as of period end |
| 2017-12-31 | $520.7K | -45.2% | 2019-04-10, Balance as of period end |
| 2016-12-31 | $951.0K | -87.6% | 2018-04-09, Balance as of period end |
| 2015-12-31 | $7.70M | +810.7% | 2017-02-15, Balance as of period end |
| 2014-12-31 | $845.2K | n/a | 2016-03-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $968.0K | -87.9% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $35.26M | +182.6% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $213.19M | +513.2% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $2.13M | +53.1% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $44.06M | +171.1% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $207.64M | +110.2% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $52.33M | -87.8% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $110.64M | -65.4% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $30.23M | +2.4% |
Compare JAGX, PRLD, CBIO, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗